https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-09-26 / Cancers (Basel) 2018 Sep;10(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-09-26 / Cancers (Basel) 2018 Sep;10(10)2018-09-26 00:00:002018-09-26 00:00:00The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-25 / Curr Oncol Rep 2018 08;20(10):80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-25 / Curr Oncol Rep 2018 08;20(10):802018-08-25 00:00:002018-08-25 00:00:00The Role of Oncolytic Viruses in the Treatment of Melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-08-05 / BMJ Open 2018 08;8(8):e021701
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-08-05 / BMJ Open 2018 08;8(8):e0217012018-08-05 00:00:002018-08-05 00:00:00Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)2018-06-04 11:43:522019-07-17 11:44:13Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-30 / Oncotarget 2018 Mar;9(24):17014-170272018-03-30 00:00:002019-02-15 08:49:53Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-26 / Oncoimmunology 2018;7(7):e1445457
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-26 / Oncoimmunology 2018;7(7):e14454572018-03-26 00:00:002018-03-26 00:00:00Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-18 / J Immunol Res 2018;2018:3982942
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-18 / J Immunol Res 2018;2018:39829422018-03-18 00:00:002019-02-15 08:49:53Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-03-06 / J Immunother Cancer 2018 Mar;6(1):19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-03-06 / J Immunother Cancer 2018 Mar;6(1):192018-03-06 00:00:002019-02-15 08:49:55Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)2018-01-25 11:36:152019-07-17 11:37:00A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-215
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-2152017-11-23 00:00:002017-11-23 00:00:00An update on the relevance of vaccine research for the treatment of metastatic melanoma